In particular, as higher volumes of scRNAseq data describing FSHD patients with different genotypes become available, the model can be updated to facilitate genotype-stratified and even personalized anti-DUX4 therapy design. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.